Q-omics provides the consensus-scored ZP3P2 profile across patient tissues and cancer cell-line models. ZP3P2 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, ZP3P2 is differentially expressed in 1, with the highest sampling consensus in HNSC. Additionally, ZP3P2 RNA expression shows 5,805 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight STAD, and HNSC as cancer lineages where ZP3P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZP3P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZP3P2 survival associations across molecular data types. ZP3P2 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZP3P2 RNA expression–survival associations across cancer types. High ZP3P2 expression shows unfavorable associations in STAD, OV, LUSC, BRCA and LIHC, but favorable associations in UCEC. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .005). Together, the overview and detailed table identify STAD as the clearest survival context for ZP3P2 RNA expression.
This table summarizes ZP3P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for ZP3P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZP3P2 shows higher tumor expression in HNSC. The HNSC box plot shows higher ZP3P2 RNA expression in tumor versus normal tissue (log2 FC = +0.006, t-test p = .033).
This table shows molecular features associated with ZP3P2 in patient tissues and cancer cell lines. In patient samples, ZP3P2 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
